Alkem Laboratories Ltd.
Snapshot View

3410.50 +30.60 ▲0.9%

05 August 2021, 04:00:00 P.M.
Volume: 7,699

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.alkemlabs.com
Financial Indicators
Market Cap 40,411.77 Cr.
Earnings per share (EPS) 132.57 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 25.50 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 616.87 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.48 Calculated using Price: 3,379.90
Dividend Yield 0.89 Period Ending 2021-03
No. of Shares Subscribed 11.96 Cr. 119,565,000 Shares
FaceValue 2
Company Profile

Alkem Laboratories is one of India’s largest generic and specialty pharmaceutical company. Also, it has consistently been ranked amongst the top ten pharmaceutical companies in India. Its portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged. Some part of its revenue is generated via offshore sales. The company has manufacturing facilities at multiple locations in India and the United States of America. Its upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.

Business area of the company

The company is one of India’s foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.

Awards and Recognition

2016:

  • Won the 'HR Tech Award for Best use of Technology in Human Resources' by World HRD Congress.
  • Won the Best Demand Planning and Forecasting Company - Pharmaceutical by ISCM's - SCMPro's in Demand Planning and Forecasting Forum Awards 2016.
  • Alkem-Pentacare division won the most enterprising company in leveraging technology in use of Mobile Applications by DigiPharmaX.
  • Brand 'Pan' received ‘Brand of the Year' award in sub-chronic category at AWACS Awards, 2016.
  • Alkem won the Guinness World Record for creating largest Blister Pack Mosiac at RSSDI Hyderabad.

2017:

  • Alkem Corporate Video won the 1st runners up award in the Best Corporate Film for driving Employee Engagement initiatives in the Mega Corporate Film Festival and Awards held in Mumbai.
  • Received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.
  • Won the People Matters league Awards - Learning & Development 2017 - Best in Cultural Transformation in Mumbai.
  • Won the Guinness world Records for creating largest Bindi Mosiac at RSSDI Bhubaneswar.
  • Won the Rising Digital Star of the Year for various digital initiatives by DigiPharmaX Awards 2017.

2018:

  • Best Innovative CSR Project at CSR Summit & Awards 2018.
  • Brand ‘Clavam’ received Brand of the Year 2018 Award at AWACS Awards for marketing excellence.
  • Business Excellence Award 2018 for Best Range of ICU Products, Pharma and Health Care Summit organized by CIMS (Current Index of Medical Specialties).

2019:

  • Express Pharma Excellence Award at Pharma CXO Summit 2011.
  • Best Use of Technology in Sales Hiring by Global Eminence Digital Awards sponsored by AQUILAA.

2020:

  • CIO Conclave and Awards 2020 in the category ‘Best IT Team of the year’.
  • Alkem Laboratories as Great Place to Work-Certified organization in the large organization category across industries.
  • India's Best Workplaces in Biotechnology & Pharmaceuticals.

Milestones

  • 1973: Inception of Alkem Laboratories.
  • 1978: First manufacturing unit was established at Taloja near Mumbai.
  • 1992: Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005.
  • 2003: First research and development facility established at Taloja.
  • 2006: Taxim became India’s first anti-infective drug to surpass annual sales figure of ` 1,000 million in the domestic market.
  • 2007: Filed the first ANDA in the United States for the drug Amlodipine.
  • 2009: Received the first ANDA approval in the United States for the drug Amlodipine.
  • 2009: Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia.
  • 2010: Acquired Ascend Laboratories, pharmaceutical company in the United States.
  • 2011: Acquired Enzene, a company engaged in the development of biosimilars in India.
  • 2012: Acquired an API manufacturing facility in the United States.
  • 2014: Acquired the ‘Clindac-A’ brand in India from Galderma S.A.
  • 2014: Clavam surpassed Rs 2,000 million domestic sales figure.
  • 2015: Acquired a formulation manufacturing facility in the United States.
  • 2015: Successfully completed Initial Public Offering (IPO).
  • 2018: Revenue from the US market crossed $ 200 million in annual sales.
  • 2019: Crossed the revenue milestone of $1 billion.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.91%
1 Week
+2.37%
1 Month
+5.03%
3 Month
+17.60%
6 Month
+16.04%
1 Year
+20.00%
2 Year
+103.76%
5 Year
+122.84%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 19.19 18.28 14.03 22.47 22.18 13.69 15.02 19.82 23.91
Return on Capital Employed (%) 14.96 14.06 13.27 23.09 21.31 17.86 16.49 18.71 22.55
Return on Assets (%) 9.92 10.14 8.16 14.59 16.61 9.91 10.66 13.92 16.66

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 2,177 2,585 2,999 3,692 4,468 4,864 5,439 6,161 7,377
Non Curr. Liab. 362 324 201 -306 -401 -359 -289 -541 -751
Curr. Liab. 1,732 1,403 2,006 1,538 1,690 2,383 2,218 3,245 3,604
Minority Int. 86 95 115 122 133 148 181
Equity & Liab. 4,271 4,311 5,291 5,018 5,872 7,010 7,501 9,013 10,411
Non Curr. Assets 2,115 2,709 2,953 2,250 2,955 2,997 3,284 3,507 3,483
Curr. Assets 2,156 1,602 2,338 2,769 2,917 4,013 4,216 5,506 6,929
Misc. Exp. not W/O
Total Assets 4,271 4,311 5,291 5,018 5,872 7,010 7,501 9,013 10,411

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 2,495 3,126 3,743 4,925 5,688 6,392 7,357 8,344 8,865
Other Income 167 165 181 240 112 115 88 104 233
Total Income 2,662 3,291 3,924 5,165 5,800 6,507 7,445 8,449 9,098
Total Expenditure -2,133 -2,716 -3,322 -4,072 -4,689 -5,383 -6,242 -6,871 -6,923
PBIDT 530 575 603 1,093 1,111 1,124 1,202 1,578 2,176
Interest -88 -93 -81 -71 -45 -55 -55 -65 -59
Depreciation -40 -52 -71 -93 -101 -143 -193 -253 -275
Taxation -18 5 -59 -176 -60 -288 -181 -110 -224
Exceptional Items
PAT 384 435 392 752 905 638 774 1,149 1,618

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 78 290 325 726 471 266 780 585 1,265
Cash Fr. Inv. -404 350 -237 202 -286 -357 -316 -741 -999
Cash Fr. Finan. 356 -600 -52 -927 -138 85 -379 79 -272
Net Change 30 41 37 1 47 -7 84 -77 -5
Cash & Cash Eqvt 57 101 140 127 167 167 249 176 174

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 66.03 66.04 66.04 65.88 62.43 62.43 62.43 60.16 58.84
Public 33.97 33.96 33.96 34.12 37.57 37.57 37.57 39.84 41.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 04 Aug 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that Alkem Laboratories Limited
(the Company) has launched Ibuprofen and Famotidine Tablets in the United States following an approval from the United States Food and Drug Administration (US FDA). A press release in this regard is enclosed herewith.

Kindly take the same on record.
Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted a remote and virtual Bio-Analytical inspection of the Companys Bioequivalence Center located at Taloja Maharashtra from
26th July 2021 to 28th July 2021.

At the end of the inspection no Form 483 was issued.

Kindly take note of the same.
Wed, 28 Jul 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to our earlier intimation dated 27th July 2021 informing that a conference call shall be held on Friday 06th August 2021 at 04.30 pm to discuss the Q1FY22 financial results please find enclosed herewith the revised details for the attending the said conference call.

Kindly take note of the same.

Technical Scans View Details

Wed, 04 Aug 2021
Higher Trade Quantity Higher Trade Quantity
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Closing Below Previous Low Closing Below Previous Low
Making Higher Highs for 3 days Making Higher Highs for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%